In late June and early July 2026, Revolution Medicines reported Phase 1/2 data showing that its RAS G12D inhibitor ...
Genuine Parts (GPC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results